Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Scioderm, Inc.
DURHAM, N.C., Oct. 21, 2013 /PRNewswire/ -- Scioderm, Inc. announced the appointment of the company's Co-Founder and CEO, Dr. Robert Ryan, to the board of directors of the Dystrophic Epidermolysis Bullosa Research Association of America (DebRA). DebRA, is the only national non-profit group dedicated to funding research and providing services and programs for those with Epidermolysis Bullosa (EB). Scioderm's lead program is an investigational therapy being evaluated for the treatment of skin blistering and erosions associated with EB, including facilitation of healing of skin lesions and reduction of the incidence and/or severity of new lesions.
"I am excited that Robert is joining the Debra of America Board of Directors," said Executive Director, Brett Kopelan. "Robert brings a wealth of experience to the Board and this will prove strategically invaluable for the organization. Furthermore Robert brings with him a great personal passion for the cause that I have no doubt will energize those around him on the Board."
"I am honored to be appointed to the board of a non-profit group dedicated to help find a cure for EB," said Robert Ryan., Ph.D., President and Chief Executive Officer of Scioderm. "I am looking forward to being an active board member and working with the DebRA organization towards raising awareness of the disease and raising funds to support research and the families with EB."
The Dystrophic Epidermolysis Bullosa Research Association of America (DebRA), is the only national non-profit dedicated to funding research and providing services and programs for those with Epidermolysis Bullosa (EB) - The Worst Disease You've Never Heard Of. ™
DebRA is dedicated to finding a cure for EB, which affects 1 out of every 20,000 live births in the United States. EB is a genetically based disease characterized by chronic, painful blistering. The skin and mucous membranes are so fragile that the slightest touch can cause severe blistering inside and outside the body.
Present at birth, EB affects men and women of all races and ethnic groups and sometimes, when there is no family history, it occurs as the result of a spontaneous genetic mutation. Today, there is no cure or treatment for EB, except daily wound care and bandaging. Genetic research is making progress towards treatments and a cure.
About Scioderm, Inc.
Scioderm is a privately held, clinical-stage pharmaceutical company focused on developing innovative therapies to address diseases with critical unmet medical needs, including orphan products. The company is headquartered in Durham, North Carolina. In 2013, Scioderm, Inc. was the first biotech to receive "Breakthrough Therapy" designation for SD-101 from the Food and Drug Administration (FDA) for the treatment of skin effects in patients with Epidermolysis Bullosa. In addition, Scioderm was recently selected as a 2013 "Fierce Top 15" company by FierceBiotech, considered as one of the top 15 emerging companies in the biotech industry. Additional information about Scioderm can be found at www.sderm.com.
SD-101 is a topical cream that has previously demonstrated potential to provide improvement in treating the severe skin effects seen in patients across all EB subtypes. An open-label Phase II study was conducted previously in children with either Simplex, Recessive Dystrophic (RDEB), or Junctional EB. The primary outcome measurements were assessment of target wound reduction and closure, and reduction in body surface area (BSA) coverage of blisters and lesions. In the clinical trial, SD-101 application resulted in complete closure of 88% of target chronic lesions within one month, in addition to a 57% reduction in BSA coverage of blisters and lesions after 3 months of daily treatment. SD-101 was well tolerated by the children, with daily administration up to 3 months.
Scioderm Forward Looking Statement
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Scioderm disclaims any intent or obligation to update these forward-looking statements.
Chief Operating Officer
©2012 PR Newswire. All Rights Reserved.